442P Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001) von Waisberg, F.D., Mando, P., Almada, C., Kassis, N., Mainella, A.C., Cermignani, L., Riggi, M.C., Winocur, M., Guercovich, A., Ayala, N.C., Micheri, C., Ituarte, A.C., Gonzalez Mattos, L., Lludgar, P., Casalnuovo, M.L., Lutteral, M.A., Cinquini, S., Gomez-Abuin, G.

Volltext